Sermorelin: What the Research Shows
Also known as: Geref, GHRH(1-29)NH2
A growth hormone-releasing hormone analog with a long history of clinical use for GH deficiency diagnosis and therapy.
This content is for educational purposes only and is not medical advice. Consult a qualified healthcare provider before making any health decisions. Full disclaimer
Quick Facts
Regulatory Status
Previously FDA-approved as a diagnostic agent for GH deficiency (Geref). The commercial product was discontinued but sermorelin remains available through compounding pharmacies.
FDA-approved indications:
- Diagnosis of growth hormone deficiency (discontinued)
Researched Applications
Key Research (1 studies cited)
Two years of continuous subcutaneous infusion of GHRH(1-29)NH2 in GH deficient adults
human pilotVittone J, et al. (1997) — Pituitary — n=9
Two-year study showing sermorelin maintained elevated IGF-1 levels and improved body composition in GH-deficient adults.
Key finding: Two years of sermorelin treatment maintained increased IGF-1 levels and improved lean body mass in GH-deficient adults.
PubMed: 9452117About this article: Written by the PeptideMark Research Team. Last reviewed 2026-03-11. All factual claims are cited to peer-reviewed sources. PubMed links open in a new tab for independent verification. Editorial methodology · Medical disclaimer
The Peptide Brief
Weekly peptide research digest. No spam.